{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:22:57Z","timestamp":1774578177809,"version":"3.50.1"},"reference-count":83,"publisher":"e-Century Publishing Corporation","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/nvym7096","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T07:28:01Z","timestamp":1764314881000},"page":"4621-4638","source":"Crossref","is-referenced-by-count":2,"title":["Gut microbiota in immunomodulation and infection prevention among multiple myeloma patients after chemotherapy: current evidence and clinical prospects"],"prefix":"10.62347","volume":"15","author":[{"given":"Huijuan","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3390\/jcm14020327","article-title":"From biology to clinical practice: the bone marrow microenvironment in multiple myeloma","volume":"14","author":"Fotiou","year":"2025","unstructured":"Fotiou D and Katodritou E. From biology to clinical practice: the bone marrow microenvironment in multiple myeloma. J Clin Med 2025; 14: 327.","journal-title":"J Clin Med"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/ejh.14356","article-title":"The role of lifestyle and environmental factors in the pathogenesis of multiple myeloma","volume":"114","author":"Suska","year":"2025","unstructured":"Suska A, Tyczyńska A, Zaucha JM, Kopińska A, Helbig G, Markiewicz M, Warzybok K, Leder E, Grosicki S, Machaliński B, Baumert B, Bator M, Usnarska-Zubkiewicz L, Fornagiel S, Ciepłuch H, Waszczuk-Gajda A, Kruczkowska-Tarantowicz K, Rzepecki P, Hus M, Morawska-Krekora A, Raźny M, Charliński G, Puła A, Nita E, Wojciechowska M, Krawczyk-Kuliś M, Goldberg J, Woźny T, Rodzaj M, Olejarz D, Gronau-Dziurkowska M, Skalniak E, Krzysztoń J, Niezabitowska K and Jurczyszyn A. The role of lifestyle and environmental factors in the pathogenesis of multiple myeloma. Eur J Haematol 2025; 114: 812-821.","journal-title":"Eur J Haematol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.14218\/jerp.2022.00059","article-title":"Multiple myeloma: risk factors, pathogenesis and relationship with anti-myeloma therapies","volume":"8","author":"Nwabuko","year":"2023","unstructured":"Nwabuko OC. Multiple myeloma: risk factors, pathogenesis and relationship with anti-myeloma therapies. J Explor Res Pharmacol 2023; 8: 57-65.","journal-title":"J Explor Res Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.3390\/curroncol30050334","article-title":"Management of multiple myeloma: a review for general practitioners in oncology","volume":"30","author":"BE","year":"2023","unstructured":"Monteith BE, Sandhu I and Lee AS. Management of multiple myeloma: a review for general practitioners in oncology. Curr Oncol 2023; 30: 4382-4401.","journal-title":"Curr Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","unstructured":"Mafra A, Laversanne M, Marcos-Gragera R, Chaves HVS, Mcshane C, Bray F and Znaor A. The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045. J Natl Cancer Inst 2025; 117: 907-914.","journal-title":"J Natl Cancer Inst"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"6829","DOI":"10.1182\/blood-2024-209627","article-title":"E3 ubiquitin ligase TRIM21 enhances macrophage-mediated bortezomib resistance by inducing M2 polarization in multiple myeloma","volume":"144","author":"Cao","year":"2024","unstructured":"Cao W, Chen J, Zhang E and Cai Z. E3 ubiquitin ligase TRIM21 enhances macrophage-mediated bortezomib resistance by inducing M2 polarization in multiple myeloma. Blood 2024; 144: 6829.","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Vasquez JF, Diaz E and Poquioma E. Assessment of 1112 newly diagnosed multiple myeloma patients according to age and year of diagnosis at a referral cancer center. Blood 2020; 136 Suppl 1: 29-30.","DOI":"10.1182\/blood-2020-142066"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s12094-020-02541-1","article-title":"A twenty-three-year population-based study","volume":"23","author":"Chang-Chan DY","year":"2021","unstructured":"Chang-Chan DY, Ríos-Tamayo R, Rodríguez Barranco M, Redondo-Sánchez D, González Y, Marcos-Gragera R and Sánchez MJ. Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study. Clin Transl Oncol 2021; 23: 1429-1439.","journal-title":"Clin Transl Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/oncolo\/oyad306","article-title":"Perspectives on the treatment of multiple myeloma","volume":"29","author":"Rafae","year":"2024","unstructured":"Rafae A, van Rhee F and Al Hadidi S. Perspectives on the treatment of multiple myeloma. Oncologist 2024; 29: 200-212.","journal-title":"Oncologist"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.32440\/ar.2023.140.01.rev08","article-title":"Initial therapy of Multiple Myeloma (MM)","volume":"140","author":"Fern&#xE1","year":"2023","unstructured":"Fernández-Rañada de la Gándara JM. Initial therapy of Multiple Myeloma (MM). Anales Ranm 2023; 140: 72-80.","journal-title":"Anales Ranm"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"115492","DOI":"10.1016\/j.ejmech.2023.115492","article-title":"Recent advance of small-molecule drugs for clinical treatment of multiple myeloma","volume":"257","author":"Zhao","year":"2023","unstructured":"Zhao JH, Xu QL, Ma S, Li CY, Zhang HC, Zhao LJ and Zhang ZY. Recent advance of small-molecule drugs for clinical treatment of multiple myeloma. Eur J Med Chem 2023; 257: 115492.","journal-title":"Eur J Med Chem"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Blimark CH, Carlson K, Day C, Einarsdottir S, Juliusson G, Karma M, Knut-Bojanowska D, Larfors G, Turesson I, Villegas-Scivetti M and Sverrisdóttir I. Risk of infections in multiple myeloma. A populationbased study on 8,672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry. Haematologica 2025; 110: 163-172.","DOI":"10.3324\/haematol.2024.285645"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2239035","DOI":"10.1080\/2162402X.2023.2239035","article-title":"Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells","volume":"12","author":"Russo","year":"2023","unstructured":"Russo M, Panini N, Fabbrizio P, Formenti L, Becchetti R, Matteo C, Meroni M, Nastasi C, Cappelleri A, Frapolli R, Nardo G, Scanziani E, Ponzetta A, Bani MR, Ghilardi C and Giavazzi R. Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells. Oncoimmunology 2023; 12: 2239035.","journal-title":"Oncoimmunology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1074779","DOI":"10.3389\/fonc.2022.1074779","article-title":"Distinct phenotype of neutrophil, monocyte, and eosinophil populations indicates altered myelopoiesis in a subset of patients with multiple myeloma","volume":"12","author":"Ong","year":"2023","unstructured":"Ong KL, Davis MD, Purnell KK, Cutshall H, Pal HC, Connelly AN, Fay CX, Kuznetsova V, Brown EE and Hel Z. Distinct phenotype of neutrophil, monocyte, and eosinophil populations indicates altered myelopoiesis in a subset of patients with multiple myeloma. Front Oncol 2023; 12: 1074779.","journal-title":"Front Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.5603\/NJO.a2023.0032","article-title":"Predicting neutropenia dynamics after radiation therapy in multiple myeloma patients receiving first-line bortezomib-based chemotherapy - a pilot study","volume":"73","author":"Mas&#x142","year":"2023","unstructured":"Masłowski M, Stawiski K, Zięba A, Mikulski D, Bednarek J and Fijuth J. Predicting neutropenia dynamics after radiation therapy in multiple myeloma patients receiving first-line bortezomib-based chemotherapy - a pilot study. Nowotwory 2023; 73: 220-229.","journal-title":"Nowotwory"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4236\/ojbd.2024.142006","article-title":"Infection in multiple myeloma: microbiological profile and prognosis in senegalese patients","volume":"14","author":"Fall","year":"2024","unstructured":"Fall S, Niang EHD, Sarr K, Camara-Tall LM, Ciss MM, Thiam A, Dakono A, Ndiaye A and Ndiaye FSD. Infection in multiple myeloma: microbiological profile and prognosis in senegalese patients. Open Journal of Blood Diseases 2024; 14: 47-58.","journal-title":"Open Journal of Blood Diseases"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1038\/s41375-024-02396-3","article-title":"Mosaic chromosomal alterations in hematopoietic cells and clinical outcomes in patients with multiple myeloma","volume":"38","author":"Husby","year":"2024","unstructured":"Husby S, Tulstrup M, Harsløf M, Nielsen C, Haastrup E, Ebbesen LH, Klarskov Andersen M, Pertesi M, Brieghel C, Niemann CU, Nilsson B, Szabo AG, Andersen NF, Abildgaard N, Vangsted A and Grønbæk K. Mosaic chromosomal alterations in hematopoietic cells and clinical outcomes in patients with multiple myeloma. Leukemia 2024; 38: 2456-2465.","journal-title":"Leukemia"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.3390\/cancers14174188","article-title":"Intestinal klebsiella pneumoniae contributes to pneumonia by synthesizing glutamine in multiple myeloma","volume":"14","author":"Wang","year":"2022","unstructured":"Wang Y, Yang Q, Zhu Y, Jian X, Guo J, Zhang J, Kuang C, Feng X, An G, Qiu L, Li G, He Y and Zhou W. Intestinal klebsiella pneumoniae contributes to pneumonia by synthesizing glutamine in multiple myeloma. Cancers (Basel) 2022; 14: 4188.","journal-title":"Cancers (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12879-024-10387-z","article-title":"co-infection in a patient with multiple myeloma treated with multiple treatment regimens","volume":"25","author":"Vrijders","year":"2025","unstructured":"Vrijders L, Ho E, Van der Beek D, Vrelust I and Nailis H. More than meets the eye: Nocardia farcinica, Candida dubliniensis and Aspergillus spp. co-infection in a patient with multiple myeloma treated with multiple treatment regimens. BMC Infect Dis 2025; 25: 156.","journal-title":"BMC Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s12885-021-08451-x","article-title":"Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019","volume":"21","author":"Balmaceda","year":"2021","unstructured":"Balmaceda N, Aziz M, Chandrasekar VT, McClune B, Kambhampati S, Shune L, Abdallah AO, Anwer F, Majeed A, Qazilbash M, Ganguly S, McGuirk J and Mohyuddin GR. Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer 2021; 21: 730.","journal-title":"BMC Cancer"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"20499361241238518","DOI":"10.1177\/20499361241238518","article-title":"Invasive fungal infections in patients with multiple myeloma: a possible growing problem in hematology and infectious diseases","volume":"11","author":"Valkovic","year":"2024","unstructured":"Valkovic T, Marcelic L and Valkovic F. Invasive fungal infections in patients with multiple myeloma: a possible growing problem in hematology and infectious diseases. Ther Adv Infect Dis 2024; 11: 20499361241238518.","journal-title":"Ther Adv Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/0002-9343(81)90303-X","article-title":"Influence of treatment and response status on infection risk in multiple myeloma","volume":"71","author":"RT","year":"1981","unstructured":"Perri RT, Hebbel RP and Oken MM. Influence of treatment and response status on infection risk in multiple myeloma. Am J Med 1981; 71: 935-940.","journal-title":"Am J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/vco.13004","article-title":"Impact of 10% dose reductions and duration of treatment delays in the management of chemotherapy-induced neutropenia in dogs treated with common chemotherapy protocols: a single-centre experience","volume":"22","author":"Busser","year":"2024","unstructured":"Busser S, Blackwood L, Pereira C, Chase-Topping M, Bavcar S and Fournier Q. Impact of 10% dose reductions and duration of treatment delays in the management of chemotherapy-induced neutropenia in dogs treated with common chemotherapy protocols: a single-centre experience. Vet Comp Oncol 2024; 22: 542-554.","journal-title":"Vet Comp Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/jpc.16538","article-title":"Burden and distribution of mortality due to sepsis and severe infection in children and adolescents in Aotearoa\/New Zealand","volume":"60","author":"McDonald","year":"2024","unstructured":"McDonald G, Hayman R and Hii J. Burden and distribution of mortality due to sepsis and severe infection in children and adolescents in Aotearoa\/New Zealand. J Paediatr Child Health 2024; 60: 113-117.","journal-title":"J Paediatr Child Health"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"917","DOI":"10.18553\/jmcp.2023.29.8.917","article-title":"Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: a retrospective US claims database analysis","volume":"29","author":"Yang","year":"2023","unstructured":"Yang J, Boytsov N, Carlson JJ and Barthold D. Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: a retrospective US claims database analysis. J Manag Care Spec Pharm 2023; 29: 917-926.","journal-title":"J Manag Care Spec Pharm"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1536778","DOI":"10.3389\/fmicb.2025.1536778","article-title":"Recent insights and advances in gut microbiota’s influence on host antiviral immunity","volume":"16","author":"Liu","year":"2025","unstructured":"Liu Y, Yan D, Chen R, Zhang Y, Wang C and Qian G. Recent insights and advances in gut microbiota’s influence on host antiviral immunity. Front Microbiol 2025; 16: 1536778.","journal-title":"Front Microbiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3892\/etm.2024.12557","article-title":"Changes in the intestinal microbiota of multiple myeloma patients living in high-altitude and cold regions analyzed using 16s rRNA highthroughput sequencing","volume":"27","author":"Liang","year":"2024","unstructured":"Liang X, Guo X, Jin H, Shen L, Ding L, Guan X, Kou Y, Wu Y and Guo H. Changes in the intestinal microbiota of multiple myeloma patients living in high-altitude and cold regions analyzed using 16s rRNA highthroughput sequencing. Exp Ther Med 2024; 27: 269.","journal-title":"Exp Ther Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1400116","DOI":"10.3389\/fnut.2024.1400116","article-title":"Causal associations between the gut microbiota and multiple myeloma: a two-sample Mendelian randomization study","volume":"11","author":"Zhang","year":"2024","unstructured":"Zhang CY, Zhang D, Sun WR, Tang HL, Tian B, Hu LH, Hu WY, Gao YY, Li MY, Xiao WT, Gao S and Gao GX. Causal associations between the gut microbiota and multiple myeloma: a two-sample Mendelian randomization study. Front Nutr 2024; 11: 1400116.","journal-title":"Front Nutr"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Zhu Y, Jian X, Chen S, An G, Jiang D, Yang Q, Zhang J, Hu J, Qiu Y, Feng X, Guo J, Chen X, Li Z, Zhou R, Hu C, He N, Shi F, Huang S, Liu H, Li X, Xie L, Zhu Y, Zhao L, Jiang Y, Li J, Wang J, Qiu L, Chen X, Jia W, He Y and Zhou W. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma. Cell Metab 2024; 36: 159-175, e158.","DOI":"10.1016\/j.cmet.2023.11.019"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1158\/2643-3230.BCD-24-0203","article-title":"Microbiota shape metabolic and immune determinants of CAR-T therapy and correlate with outcomes in myeloma","volume":"6","author":"Uribe-Herranz M","year":"2025","unstructured":"Uribe-Herranz M, Oliver-Caldés A, Martínez-Micaelo N, Español-Rego M, Val-Casals M, Martínez-Soler R, Rubio-Garcia E, Brunello V, Mihelic EZ, Klein-González N, Benítez-Ribas D, Amigó N, Vergara A, Ortiz-Maldonado V, Rodríguez-Lobato LG, Delgado J, Ortiz de Landazuri I, González-Calle V, Cabañas V, Martin-Antonio B, Pérez-Amill L, Reguera-Ortega JL, Rodríguez-Otero P, Paiva B, Martínez-López J, Mateos MV, Pascal M, Urbano-Ispizua Á, González-Navarro EA, Fernández de Larrea C and Juan M. Microbiota shape metabolic and immune determinants of CAR-T therapy and correlate with outcomes in myeloma. Blood Cancer Discov 2025; 6: 484-504.","journal-title":"Blood Cancer Discov"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"5281","DOI":"10.1007\/s00203-021-02516-y","article-title":"Structural diversity, functional aspects and future therapeutic applications of human gut microbiome","volume":"203","author":"Ghosh","year":"2021","unstructured":"Ghosh S and Pramanik S. Structural diversity, functional aspects and future therapeutic applications of human gut microbiome. Arch Microbiol 2021; 203: 5281-5308.","journal-title":"Arch Microbiol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"8269","DOI":"10.12659\/MSM.919988","article-title":"Fecal microbiota taxonomic shifts in chinese multiple myeloma patients analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA high-throughput sequencing","volume":"25","author":"Zhang","year":"2019","unstructured":"Zhang B, Gu J, Liu J, Huang B and Li J. Fecal microbiota taxonomic shifts in chinese multiple myeloma patients analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA high-throughput sequencing. Med Sci Monit 2019; 25: 8269-8280.","journal-title":"Med Sci Monit"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40168-020-00854-5","article-title":"Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria","volume":"8","author":"Jian","year":"2020","unstructured":"Jian X, Zhu Y, Ouyang J, Wang Y, Lei Q, Xia J, Guan Y, Zhang J, Guo J, He Y, Wang J, Li J, Lin J, Su M, Li G, Wu M, Qiu L, Xiang J, Xie L, Jia W and Zhou W. Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria. Microbiome 2020; 8: 74.","journal-title":"Microbiome"},{"key":"ref33","unstructured":"Mirijello A, Impagnatiello M, Zaccone V, Ventura G, Pompa L, Addolorato G and Landolfi R; Internal Medicine Sepsis Study Group. Catheter-related bloodstream infections by opportunistic pathogens in immunocompromised hosts. Eur Rev Med Pharmacol Sci 2015; 19: 2440-2445."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1346211","DOI":"10.3389\/fimmu.2024.1346211","article-title":"Different evasion strategies in multiple myeloma","volume":"15","author":"Wang","year":"2024","unstructured":"Wang C, Wang W, Wang M, Deng J, Sun C, Hu Y and Luo S. Different evasion strategies in multiple myeloma. Front Immunol 2024; 15: 1346211.","journal-title":"Front Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1575509","DOI":"10.3389\/fimmu.2025.1575509","article-title":"Dendritic cells in multiple myeloma: from immune evasion to therapeutic potential","volume":"16","author":"MA","year":"2025","unstructured":"Jordan MA, Morschl J and Autenrieth SE. Dendritic cells in multiple myeloma: from immune evasion to therapeutic potential. Front Immunol 2025; 16: 1575509.","journal-title":"Front Immunol"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Gabrielli G, Shouval R, Ghilardi G, van den Brink M and Ruella M. Harnessing the gut microbiota to potentiate the efficacy of CAR T cell therapy. Hemasphere 2023; 7: e950.","DOI":"10.1097\/HS9.0000000000000950"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","article-title":"Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer","volume":"28","author":"Derosa","year":"2022","unstructured":"Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Moro-Sibilot D, Goldwasser F, Silva CAC, Terrisse S, Bonvalet M, Scherpereel A, Pegliasco H, Richard C, Ghiringhelli F, Elkrief A, Desilets A, Blanc-Durand F, Cumbo F, Blanco A, Boidot R, Chevrier S, Daillère R, Kroemer G, Alla L, Pons N, Le Chatelier E, Galleron N, Roume H, Dubuisson A, Bouchard N, Messaoudene M, Drubay D, Deutsch E, Barlesi F, Planchard D, Segata N, Martinez S, Zitvogel L, Soria JC and Besse B. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med 2022; 28: 315-324.","journal-title":"Nat Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1169541","DOI":"10.3389\/fimmu.2023.1169541","article-title":"Therapeutic strategies to enhance immune response induced by multiple myeloma cells","volume":"14","author":"Liu","year":"2023","unstructured":"Liu Z, Yang C, Liu X, Xu X, Zhao X and Fu R. Therapeutic strategies to enhance immune response induced by multiple myeloma cells. Front Immunol 2023; 14: 1169541.","journal-title":"Front Immunol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple myeloma: signaling pathways and targeted therapy","volume":"5","author":"Lu","year":"2024","unstructured":"Lu Q, Yang D, Li H, Niu T and Tong A. Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed 2024; 5: 25.","journal-title":"Mol Biomed"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Han D, Wang W, Gong J, Ma Y and Li Y. Microbiota metabolites in bone: shaping health and confronting disease. Heliyon 2024; 10: e28435.","DOI":"10.1016\/j.heliyon.2024.e28435"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/rai2.12088","article-title":"Madecassic acid suppresses osteoclast differentiation and bone resorption by inhibiting RANKL-induced NF-κB, JNK and NFAT signaling pathways","volume":"3","author":"Su","year":"2023","unstructured":"Su P, Luo X, Zeng C and Zhou L. Madecassic acid suppresses osteoclast differentiation and bone resorption by inhibiting RANKL-induced NF-κB, JNK and NFAT signaling pathways. Rheumatology & Autoimmunity 2023; 3: 220-229.","journal-title":"Rheumatology &#x0026 Autoimmunity"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1271001","DOI":"10.3389\/fphar.2023.1271001","article-title":"Short-chain fatty acids are potential goalkeepers of atherosclerosis","volume":"14","author":"Feng","year":"2023","unstructured":"Feng Y and Xu D. Short-chain fatty acids are potential goalkeepers of atherosclerosis. Front Pharmacol 2023; 14: 1271001.","journal-title":"Front Pharmacol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.3390\/jcm13133885","article-title":"Microbiota-derived short-chain fatty acids boost antitumoral natural killer cell activity","volume":"13","author":"P&#xE9","year":"2024","unstructured":"Pérez M, Buey B, Corral P, Giraldos D and Latorre E. Microbiota-derived short-chain fatty acids boost antitumoral natural killer cell activity. J Clin Med 2024; 13: 3885.","journal-title":"J Clin Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41375-021-01422-y","article-title":"Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression","volume":"36","author":"Dahlhoff","year":"2022","unstructured":"Dahlhoff J, Manz H, Steinfatt T, Delgado-Tascon J, Seebacher E, Schneider T, Wilnit A, Mokhtari Z, Tabares P, Böckle D, Rasche L, Martin Kortüm K, Lutz MB, Einsele H, Brandl A and Beilhack A. Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression. Leukemia 2022; 36: 790-800.","journal-title":"Leukemia"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"853540","DOI":"10.3389\/fimmu.2022.853540","article-title":"The role of the crosstalk between gut microbiota and immune cells in the pathogenesis and treatment of multiple myeloma","volume":"13","author":"Jasi&#x144","year":"2022","unstructured":"Jasiński M, Biliński J and Basak GW. The role of the crosstalk between gut microbiota and immune cells in the pathogenesis and treatment of multiple myeloma. Front Immunol 2022; 13: 853540.","journal-title":"Front Immunol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1186892","DOI":"10.3389\/fimmu.2023.1186892","article-title":"Regulation of short-chain fatty acids in the immune system","volume":"14","author":"Liu","year":"2023","unstructured":"Liu XF, Shao JH, Liao YT, Wang LN, Jia Y, Dong PJ, Liu ZZ, He DD, Li C and Zhang X. Regulation of short-chain fatty acids in the immune system. Front Immunol 2023; 14: 1186892.","journal-title":"Front Immunol"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Ahmed N, Ghannoum M, Gallogly M, de Lima M and Malek E. Influence of gut microbiome on multiple myeloma: friend or foe? J Immunother Cancer 2020; 8: e000576.","DOI":"10.1136\/jitc-2020-000576"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1058272","DOI":"10.3389\/fimmu.2022.1058272","article-title":"Gut microbiome in multiple myeloma: mechanisms of progression and clinical applications","volume":"13","author":"Zhang","year":"2022","unstructured":"Zhang L, Xiang Y, Li Y and Zhang J. Gut microbiome in multiple myeloma: mechanisms of progression and clinical applications. Front Immunol 2022; 13: 1058272.","journal-title":"Front Immunol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2276314","DOI":"10.1080\/19490976.2023.2276314","article-title":"Gut microbiota and tumor-associated macrophages: potential in tumor diagnosis and treatment","volume":"15","author":"Zhou","year":"2023","unstructured":"Zhou D and Li Y. Gut microbiota and tumor-associated macrophages: potential in tumor diagnosis and treatment. Gut Microbes 2023; 15: 2276314.","journal-title":"Gut Microbes"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"15531","DOI":"10.1096\/fj.202000162R","article-title":"Metabolism of short-chain fatty acid propionate induces surface expression of NKG2D ligands on cancer cells","volume":"34","author":"H&#xF8","year":"2020","unstructured":"Høgh RI, Møller SH, Jepsen SD, Mellergaard M, Lund A, Pejtersen M, Fitzner E, Andresen L and Skov S. Metabolism of short-chain fatty acid propionate induces surface expression of NKG2D ligands on cancer cells. FASEB J 2020; 34: 15531-15546.","journal-title":"FASEB J"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1185787","DOI":"10.3389\/fmicb.2023.1185787","article-title":"Role of the gut microbiota in hematologic cancer","volume":"14","author":"Guevara-Ram&#xED","year":"2023","unstructured":"Guevara-Ramírez P, Cadena-Ullauri S, Paz-Cruz E, Tamayo-Trujillo R, Ruiz-Pozo VA and Zambrano AK. Role of the gut microbiota in hematologic cancer. Front Microbiol 2023; 14: 1185787.","journal-title":"Front Microbiol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/s41423-024-01230-1","article-title":"Kynurenine-AhR reduces T-cell infiltration and induces a delayed T-cell immune response by suppressing the STAT1-CXCL9\/CXCL10 axis in tuberculosis","volume":"21","author":"Liu","year":"2024","unstructured":"Liu X, Yang M, Xu P, Du M, Li S, Shi J, Li Q, Yuan J and Pang Y. Kynurenine-AhR reduces T-cell infiltration and induces a delayed T-cell immune response by suppressing the STAT1-CXCL9\/CXCL10 axis in tuberculosis. Cell Mol Immunol 2024; 21: 1426-1440.","journal-title":"Cell Mol Immunol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/hon.3108","article-title":"Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients","volume":"41","author":"Asano","year":"2023","unstructured":"Asano A, Ri M, Masaki A, Maeda Y, Tachita T, Hirade K, Marumo Y, Nakashima T, Hagiwara S, Kinoshita S, Suzuki T, Narita T, Kusumoto S, Komatsu H, Inagaki H and Iida S. Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients. Hematol Oncol 2023; 41: 424-433.","journal-title":"Hematol Oncol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000500976","article-title":"The human microbiota in multiple myeloma and proteasome inhibitors","volume":"143","author":"Alkharabsheh","year":"2020","unstructured":"Alkharabsheh O, Sidiqi MH, Aljama MA, Gertz MA and Frankel AE. The human microbiota in multiple myeloma and proteasome inhibitors. Acta Haematol 2020; 143: 118-123.","journal-title":"Acta Haematol"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"McLeod JR, Harvey PA and Detweiler CS. An oral fluorouracil prodrug, capecitabine, mitigates a gram-positive systemic infection in mice. Microbiol Spectr 2021; 9: e0027521.","DOI":"10.1128\/Spectrum.00275-21"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Aarnoutse R, Ziemons J, de Vos-Geelen J, Valkenburg-van Iersel L, Wildeboer ACL, Vievermans A, Creemers GM, Baars A, Vestjens HJHMJ, Le GN, Barnett DJM, Rensen SS, Penders J and Smidt ML. The role of intestinal microbiota in metastatic colorectal cancer patients treated with capecitabine. Clin Colorectal Cancer 2022; 21: e87-e97.","DOI":"10.1016\/j.clcc.2021.10.004"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","unstructured":"Zhang C, Xu C, Gao X and Yao Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics 2022; 12: 2115-2132.","journal-title":"Theranostics"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/mi.2016.75","article-title":"Mechanisms of inflammation-driven bacterial dysbiosis in the gut","volume":"10","author":"MY","year":"2017","unstructured":"Zeng MY, Inohara N and Nuñez G. Mechanisms of inflammation-driven bacterial dysbiosis in the gut. Mucosal Immunol 2017; 10: 18-26.","journal-title":"Mucosal Immunol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s12602-021-09795-3","article-title":"Probiotic Therapy (BIO-THREE) mitigates intestinal microbial imbalance and intestinal damage caused by oxaliplatin","volume":"14","author":"Yuan","year":"2022","unstructured":"Yuan W, Xiao X, Yu X, Xie F, Feng P, Malik K, Wu J, Ye Z, Zhang P and Li X. Probiotic Therapy (BIO-THREE) mitigates intestinal microbial imbalance and intestinal damage caused by oxaliplatin. Probiotics Antimicrob Proteins 2022; 14: 60-71.","journal-title":"Probiotics Antimicrob Proteins"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"English J, Connolly L and Stewart LD. Increased intestinal permeability: an avenue for the development of autoimmune disease? Exposure and Health 2024; 16: 575-605.","DOI":"10.1007\/s12403-023-00578-5"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Liu T, Wu Y, Wang L, Pang X, Zhao L, Yuan H and Zhang C. A more robust gut microbiota in calorie-restricted mice is associated with attenuated intestinal injury caused by the chemotherapy drug cyclophosphamide. mBio 2019; 10: e02903-02918.","DOI":"10.1128\/mBio.02903-18"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.3390\/cancers15071942","article-title":"The interaction between gut microbiota and host amino acids metabolism in multiple myeloma","volume":"15","author":"Yang","year":"2023","unstructured":"Yang Q, Wei Y, Zhu Y, Guo J, Zhang J, He Y, Li X, Liu J and Zhou W. The interaction between gut microbiota and host amino acids metabolism in multiple myeloma. Cancers (Basel) 2023; 15: 1942.","journal-title":"Cancers (Basel)"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"152398","DOI":"10.1016\/j.seminoncol.2025.152398","article-title":"The effects of microbiota-derived short-chain fatty acids on T lymphocytes: from autoimmune diseases to cancer","volume":"52","author":"Saadh","year":"2025","unstructured":"Saadh MJ, Allela OQB, Ballal S, Mahdi MS, Chahar M, Verma R, Al-Hussein RKA, Adil M, Jawad MJ and Al-Nuaimi AMA. The effects of microbiota-derived short-chain fatty acids on T lymphocytes: from autoimmune diseases to cancer. Semin Oncol 2025; 52: 152398.","journal-title":"Semin Oncol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1243997","DOI":"10.3389\/fimmu.2023.1243997","article-title":"Molecular and immunological mechanisms of clonal evolution in multiple myeloma","volume":"14","author":"Forster","year":"2023","unstructured":"Forster S, Radpour R and Ochsenbein AF. Molecular and immunological mechanisms of clonal evolution in multiple myeloma. Front Immunol 2023; 14: 1243997.","journal-title":"Front Immunol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1758835918821021","DOI":"10.1177\/1758835918821021","article-title":"D-methionine alleviates cisplatin-induced mucositis by restoring the gut microbiota structure and improving intestinal inflammation","volume":"11","author":"CH","year":"2019","unstructured":"Wu CH, Ko JL, Liao JM, Huang SS, Lin MY, Lee LH, Chang LY and Ou CC. D-methionine alleviates cisplatin-induced mucositis by restoring the gut microbiota structure and improving intestinal inflammation. Ther Adv Med Oncol 2019; 11: 1758835918821021.","journal-title":"Ther Adv Med Oncol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/apt.13302","article-title":"Chemotherapy-driven dysbiosis in the intestinal microbiome","volume":"42","author":"Montassier","year":"2015","unstructured":"Montassier E, Gastinne T, Vangay P, Al-Ghalith GA, Bruley des Varannes S, Massart S, Moreau P, Potel G, de La Cochetière MF, Batard E and Knights D. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther 2015; 42: 515-528.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.clnu.2015.11.008","article-title":"Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients","volume":"36","author":"Motoori","year":"2017","unstructured":"Motoori M, Yano M, Miyata H, Sugimura K, Saito T, Omori T, Fujiwara Y, Miyoshi N, Akita H, Gotoh K, Takahashi H, Kobayashi S, Noura S, Ohue M, Asahara T, Nomoto K, Ishikawa O and Sakon M. Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. Clin Nutr 2017; 36: 93-99.","journal-title":"Clin Nutr"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3390\/antibiotics11111521","article-title":"The influence of the gut microbiome in paediatric cancer origin and treatment","volume":"11","author":"S&#xE1","year":"2022","unstructured":"Sági V, Makra N, Csoszánszki N, Decmann A, Szabó D and Garami M. The influence of the gut microbiome in paediatric cancer origin and treatment. Antibiotics (Basel) 2022; 11: 1521.","journal-title":"Antibiotics (Basel)"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"9592","DOI":"10.3390\/ijms24119592","article-title":"Mucositis and infection in hematology patients","volume":"24","author":"Blijlevens","year":"2023","unstructured":"Blijlevens NMA and de Mooij CEM. Mucositis and infection in hematology patients. Int J Mol Sci 2023; 24: 9592.","journal-title":"Int J Mol Sci"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1021\/acsinfecdis.4c00841","article-title":"Call for papers: the role of microbiota in infection and immunity","volume":"10","author":"Griffin","year":"2024","unstructured":"Griffin M, Hatzios S and Qiao Y. Call for papers: the role of microbiota in infection and immunity. ACS Infect Dis 2024; 10: 3714.","journal-title":"ACS Infect Dis"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"572912","DOI":"10.3389\/fcimb.2020.572912","article-title":"Antibiotics as major disruptors of gut microbiota","volume":"10","author":"Ramirez","year":"2020","unstructured":"Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL and Cohen H. Antibiotics as major disruptors of gut microbiota. Front Cell Infect Microbiol 2020; 10: 572912.","journal-title":"Front Cell Infect Microbiol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1158\/1078-0432.CCR-23-0195","article-title":"Short-chain fatty acid production by gut microbiota predicts treatment response in multiple myeloma","volume":"30","author":"Rodr&#xED","year":"2024","unstructured":"Rodríguez-García A, Arroyo A, García-Vicente R, Morales ML, Gómez-Gordo R, Justo P, Cuéllar C, Sánchez-Pina J, López N, Alonso R, Puig N, Mateos MV, Ayala R, Gómez-Garre D, Martínez-López J and Linares M. Short-chain fatty acid production by gut microbiota predicts treatment response in multiple myeloma. Clin Cancer Res 2024; 30: 904-917.","journal-title":"Clin Cancer Res"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"31221","DOI":"10.1038\/s41598-024-82589-z","article-title":"Impact of gut colonization by antibiotic-resistant bacteria on the outcomes of autologous stem cell transplantation in multiple myeloma","volume":"14","author":"Jasi&#x144","year":"2024","unstructured":"Jasiński M, Biliński J, Maciejewska M, Ostrowska K, Rusicka-Krzewska P, Konarski W, Podsiadły E, Snarski E and Basak GW. Impact of gut colonization by antibiotic-resistant bacteria on the outcomes of autologous stem cell transplantation in multiple myeloma. Sci Rep 2024; 14: 31221.","journal-title":"Sci Rep"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41413-022-00215-y","article-title":"Ammonia promotes the proliferation of bone marrow-derived mesenchymal stem cells by regulating the Akt\/mTOR\/S6k pathway","volume":"10","author":"Liu","year":"2022","unstructured":"Liu Y, Zhang X, Wang W, Liu T, Ren J, Chen S, Lu T, Tie Y, Yuan X, Mo F, Yang J, Wei Y and Wei X. Ammonia promotes the proliferation of bone marrow-derived mesenchymal stem cells by regulating the Akt\/mTOR\/S6k pathway. Bone Res 2022; 10: 57.","journal-title":"Bone Res"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Cardoso Brito AS, Alves Vieira GI, Souza dos Santos A and Barbosa da Silva AM. ProbiÓticos No Tratamento Do Mieloma MÚltiplo: Uma RevisÃo. RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218 2024; 5: e565340.","DOI":"10.47820\/recima21.v5i6.5340"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"845422","DOI":"10.3389\/fimmu.2022.845422","article-title":"The insider: impact of the gut microbiota on cancer immunity and response to therapies in multiple myeloma","volume":"13","author":"Brevi","year":"2022","unstructured":"Brevi A, Cogrossi LL, Lorenzoni M, Mattorre B and Bellone M. The insider: impact of the gut microbiota on cancer immunity and response to therapies in multiple myeloma. Front Immunol 2022; 13: 845422.","journal-title":"Front Immunol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"853540","DOI":"10.3389\/fimmu.2022.853540","article-title":"The role of the crosstalk between gut microbiota and immune cells in the pathogenesis and treatment of multiple myeloma","volume":"13","author":"Jasi&#x144","year":"2022","unstructured":"Jasiński M, Biliński J and Basak GW. The role of the crosstalk between gut microbiota and immune cells in the pathogenesis and treatment of multiple myeloma. Front Immunol 2022; 13: 853540.","journal-title":"Front Immunol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3389\/fimmu.2020.00575","article-title":"Intestinal flora and disease mutually shape the regional immune system in the intestinal tract","volume":"11","author":"Zhou","year":"2020","unstructured":"Zhou B, Yuan Y, Zhang S, Guo C, Li X, Li G, Xiong W and Zeng Z. Intestinal flora and disease mutually shape the regional immune system in the intestinal tract. Front Immunol 2020; 11: 575.","journal-title":"Front Immunol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1413485","DOI":"10.3389\/fimmu.2024.1413485","article-title":"Crosstalk between gut microbiota and host immune system and its response to traumatic injury","volume":"15","author":"Ullah","year":"2024","unstructured":"Ullah H, Arbab S, Tian Y, Chen Y, Liu CQ, Li Q and Li K. Crosstalk between gut microbiota and host immune system and its response to traumatic injury. Front Immunol 2024; 15: 1413485.","journal-title":"Front Immunol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"103114","DOI":"10.1016\/j.jaut.2023.103114","article-title":"The gut ecosystem and immune tolerance","volume":"141","author":"Shao","year":"2023","unstructured":"Shao T, Hsu R, Rafizadeh DL, Wang L, Bowlus CL, Kumar N, Mishra J, Timilsina S, Ridgway WM, Gershwin ME, Ansari AA, Shuai Z and Leung PSC. The gut ecosystem and immune tolerance. J Autoimmun 2023; 141: 103114.","journal-title":"J Autoimmun"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","article-title":"Interaction between microbiota and immunity in health and disease","volume":"30","author":"Zheng","year":"2020","unstructured":"Zheng D, Liwinski T and Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res 2020; 30: 492-506.","journal-title":"Cell Res"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10585-024-10305-2","article-title":"Multiple myeloma: clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics","volume":"41","author":"MH","year":"2024","unstructured":"Elbahoty MH, Papineni B and Samant RS. Multiple myeloma: clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics. Clin Exp Metastasis 2024; 41: 829-842.","journal-title":"Clin Exp Metastasis"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/11\/ajcr0168715.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T02:16:33Z","timestamp":1768961793000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/11\/ajcr0168715.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":83,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/nvym7096","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}